

Peter A Kavsak

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9372380/publications.pdf>

Version: 2024-02-01

239
papers

8,678
citations

94415

37
h-index

49904

87
g-index

241
all docs

241
docs citations

241
times ranked

7785
citing authors

#	ARTICLE	IF	CITATIONS
1	Smad7 Binds to Smurf2 to Form an E3 Ubiquitin Ligase that Targets the TGF β 2 Receptor for Degradation. <i>Molecular Cell</i> , 2000, 6, 1365-1375.	9.7	1,219
2	A SMAD ubiquitin ligase targets the BMP pathway and affects embryonic pattern formation. <i>Nature</i> , 1999, 400, 687-693.	27.8	762
3	Myocardial Injury after Noncardiac Surgery. <i>Anesthesiology</i> , 2014, 120, 564-578.	2.5	740
4	Association of Postoperative High-Sensitivity Troponin Levels With Myocardial Injury and 30-Day Mortality Among Patients Undergoing Noncardiac Surgery. <i>JAMA - Journal of the American Medical Association</i> , 2017, 317, 1642.	7.4	579
5	Clinical Laboratory Practice Recommendations for the Use of Cardiac Troponin in Acute Coronary Syndrome: Expert Opinion from the Academy of the American Association for Clinical Chemistry and the Task Force on Clinical Applications of Cardiac Bio-Markers of the International Federation of Clinical Chemistry and Laboratory Medicine. <i>Clinical Chemistry</i> , 2018, 64, 645-655.	3.2	327
6	TGF- β 2 induces assembly of a Smad2-Smurf2 ubiquitin ligase complex that targets SnoN for degradation. <i>Nature Cell Biology</i> , 2001, 3, 587-595.	10.3	297
7	Regulation of Smurf2 Ubiquitin Ligase Activity by Anchoring the E2 to the HECT Domain. <i>Molecular Cell</i> , 2005, 19, 297-308.	9.7	250
8	Application of High-Sensitivity Troponin in Suspected Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019, 380, 2529-2540.	27.0	230
9	Association of High-Sensitivity Cardiac Troponin I Concentration With Cardiac Outcomes in Patients With Suspected Acute Coronary Syndrome. <i>JAMA - Journal of the American Medical Association</i> , 2017, 318, 1913.	7.4	188
10	Assessing the Requirement for the 6-Hour Interval between Specimens in the American Heart Association Classification of Myocardial Infarction in Epidemiology and Clinical Research Studies. <i>Clinical Chemistry</i> , 2006, 52, 812-818.	3.2	179
11	Analytic and Clinical Utility of a Next-Generation, Highly Sensitive Cardiac Troponin I Assay for Early Detection of Myocardial Injury. <i>Clinical Chemistry</i> , 2009, 55, 573-577.	3.2	165
12	Plasma IL-6 and IL-10 Concentrations Predict AKI and Long-Term Mortality in Adults after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2015, 26, 3123-3132.	6.1	144
13	Assessment of the European Society of Cardiology 0-Hour/1-Hour Algorithm to Rule-Out and Rule-In Acute Myocardial Infarction. <i>Circulation</i> , 2016, 134, 1532-1541.	1.6	111
14	Preoperative N-Terminal Pro-B-Type Natriuretic Peptide and Cardiovascular Events After Noncardiac Surgery. <i>Annals of Internal Medicine</i> , 2020, 172, 96.	3.9	99
15	Short- and Long-Term Risk Stratification Using a Next-Generation, High-Sensitivity Research Cardiac Troponin I (hs-cTnI) Assay in an Emergency Department Chest Pain Population. <i>Clinical Chemistry</i> , 2009, 55, 1809-1815.	3.2	88
16	High sensitivity troponin T concentrations in patients undergoing noncardiac surgery: A prospective cohort study. <i>Clinical Biochemistry</i> , 2011, 44, 1021-1024.	1.9	84
17	Validation of presentation and 3-h high-sensitivity troponin to rule-in and rule-out acute myocardial infarction. <i>Heart</i> , 2016, 102, 1270-1278.	2.9	82
18	The impact of the ESC/ACC redefinition of myocardial infarction and new sensitive troponin assays on the frequency of acute myocardial infarction. <i>American Heart Journal</i> , 2006, 152, 118-125.	2.7	79

#	ARTICLE	IF	CITATIONS
19	High-Sensitivity Cardiac Troponin I Measurement for Risk Stratification in a Stable High-Risk Population. <i>Clinical Chemistry</i> , 2011, 57, 1146-1153.	3.2	78
20	High-Sensitivity Troponin I after Cardiac Surgery and 30-Day Mortality. <i>New England Journal of Medicine</i> , 2022, 386, 827-836.	27.0	69
21	Long-Term Health Outcomes Associated with Detectable Troponin I Concentrations. <i>Clinical Chemistry</i> , 2007, 53, 220-227.	3.2	67
22	Effects of contemporary troponin assay sensitivity on the utility of the early markers myoglobin and CKMB isoforms in evaluating patients with possible acute myocardial infarction. <i>Clinica Chimica Acta</i> , 2007, 380, 213-216.	1.1	63
23	Variability and Error in Cardiac Troponin Testing. <i>American Journal of Clinical Pathology</i> , 2017, 148, 281-295.	0.7	63
24	Interleukin-6 and interleukin-10 as acute kidney injury biomarkers in pediatric cardiac surgery. <i>Pediatric Nephrology</i> , 2015, 30, 1519-1527.	1.7	62
25	Relationship of Kidney Injury Biomarkers with Long-Term Cardiovascular Outcomes after Cardiac Surgery. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 3699-3707.	6.1	59
26	Risk Stratification for Heart Failure and Death in an Acute Coronary Syndrome Population Using Inflammatory Cytokines and N-Terminal Pro-Brain Natriuretic Peptide. <i>Clinical Chemistry</i> , 2007, 53, 2112-2118.	3.2	55
27	Cardiac Biomarkers and Acute Kidney Injury After Cardiac Surgery. <i>Pediatrics</i> , 2015, 135, e945-e956.	2.1	53
28	Plasma Monocyte Chemoattractant Protein-1 Is Associated With Acute Kidney Injury and Death After Cardiac Operations. <i>Annals of Thoracic Surgery</i> , 2017, 104, 613-620.	1.3	52
29	Elevated C-reactive protein in acute coronary syndrome presentation is an independent predictor of long-term mortality and heart failure. <i>Clinical Biochemistry</i> , 2007, 40, 326-329.	1.9	49
30	Acceptable Analytical Variation May Exceed High-Sensitivity Cardiac Troponin I Cutoffs in Early Rule-Out and Rule-In Acute Myocardial Infarction Algorithms. <i>Clinical Chemistry</i> , 2016, 62, 887-889.	3.2	47
31	Simulation Models of Misclassification Error for Single Thresholds of High-Sensitivity Cardiac Troponin I Due to Assay Bias and Imprecision. <i>Clinical Chemistry</i> , 2017, 63, 585-592.	3.2	46
32	Predicting myocardial infarction and other serious cardiac outcomes using high-sensitivity cardiac troponin T in a high-risk stable population. <i>Clinical Biochemistry</i> , 2013, 46, 5-9.	1.9	44
33	Total Analytic Error for Low Cardiac Troponin Concentrations (≤ 10 ng/L) by Use of a High-Sensitivity Cardiac Troponin Assay. <i>Clinical Chemistry</i> , 2017, 63, 1043-1045.	3.2	42
34	High-Sensitivity Generation 5 Cardiac Troponin T Sex- and Age-Specific 99th Percentiles in the CALIPER Cohort of Healthy Children and Adolescents. <i>Clinical Chemistry</i> , 2019, 65, 589-591.	3.2	42
35	Macrocomplexes and discordant high-sensitivity cardiac troponin concentrations. <i>Annals of Clinical Biochemistry</i> , 2018, 55, 500-504.	1.6	41
36	A practical approach for the validation and clinical implementation of a high-sensitivity cardiac troponin I assay across a North American city. <i>Practical Laboratory Medicine</i> , 2015, 1, 28-34.	1.3	38

#	ARTICLE	IF	CITATIONS
37	Clinical chemistry score versus high-sensitivity cardiac troponin I and T tests alone to identify patients at low or high risk for myocardial infarction or death at presentation to the emergency department. <i>Cmaj</i> , 2018, 190, E974-E984.	2.0	38
38	Performance of the European Society of Cardiology 0/1-Hour, 0/2-Hour, and 0/3-Hour Algorithms for Rapid Triage of Acute Myocardial Infarction. <i>Annals of Internal Medicine</i> , 2022, 175, 101-113.	3.9	37
39	Increasing Cardiac Troponin Changes Measured by a Research High-Sensitivity Troponin I Assay: Absolute vs Percentage Changes and Long-Term Outcomes in a Chest Pain Cohort. <i>Clinical Chemistry</i> , 2010, 56, 1902-1904.	3.2	36
40	Rule-In and Rule-Out of Myocardial Infarction Using Cardiac Troponin and Glycemic Biomarkers in Patients with Symptoms Suggestive of Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2017, 63, 403-414.	3.2	36
41	Association of cardiac biomarkers with acute kidney injury after cardiac surgery: A multicenter cohort study. <i>Journal of Thoracic and Cardiovascular Surgery</i> , 2016, 152, 245-251.e4.	0.8	35
42	2007 Universal Myocardial Infarction Definition Change Criteria for Risk Stratification by Use of a High-Sensitivity Cardiac Troponin I Assay. <i>Clinical Chemistry</i> , 2010, 56, 487-489.	3.2	34
43	Cardiac troponin and natriuretic peptide analytical interferences from hemolysis and biotin: educational aids from the IFCC Committee on Cardiac Biomarkers (IFCC C-CB). <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 633-640.	2.3	33
44	Implications of adjustment of high-sensitivity cardiac troponin T assay. <i>Clinical Chemistry</i> , 2013, 59, 574-576.	3.2	32
45	Undetectable Concentrations of a Food and Drug Administration-approved High-sensitivity Cardiac Troponin T Assay to Rule Out Acute Myocardial Infarction at Emergency Department Arrival. <i>Academic Emergency Medicine</i> , 2017, 24, 1267-1277.	1.8	32
46	Incomplete pediatric reference intervals for the management of patients with inborn errors of metabolism. <i>Clinical Biochemistry</i> , 2006, 39, 595-599.	1.9	31
47	Cardiac troponin testing in the acute care setting: Ordering, reporting, and high sensitivity assays—An update from the Canadian society of clinical chemists (CSCC). <i>Clinical Biochemistry</i> , 2011, 44, 1273-1277.	1.9	30
48	Contemporary Emergency Department Management of Patients with Chest Pain: A Concise Review and Guide for the High-Sensitivity Troponin Era. <i>Canadian Journal of Cardiology</i> , 2018, 34, 98-108.	1.7	30
49	A randomized phase II study of cediranib alone versus cediranib in combination with dasatinib in docetaxel resistant, castration resistant prostate cancer patients. <i>Investigational New Drugs</i> , 2014, 32, 1005-1016.	2.6	29
50	Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study establishing diagnostic criteria and prognostic importance. <i>British Journal of Anaesthesia</i> , 2021, 126, 163-171.	3.4	29
51	Assessing matrix, interferences and comparability between the Abbott Diagnostics and the Beckman Coulter high-sensitivity cardiac troponin I assays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 56, 1176-1181.	2.3	28
52	Getting Cardiac Troponin Right: Appraisal of the 2020 European Society of Cardiology Guidelines for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation by the International Federation of Clinical Chemistry and Laboratory Medicine Committee on Clinical Applications of Cardiac Bio-Markers. <i>Clinical Chemistry</i> , 2021, 67, 730-735.	3.2	28
53	Comparative Evaluation of 2-Hour Rapid Diagnostic Algorithms for Acute Myocardial Infarction Using High-Sensitivity Cardiac Troponin T. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1006-1012.	1.7	27
54	Evaluation of the Siemens ADVIA Centaur high-sensitivity cardiac troponin I assay in serum. <i>Clinica Chimica Acta</i> , 2018, 487, 216-221.	1.1	27

#	ARTICLE	IF	CITATIONS
55	PAPP-A as a marker of increased long-term risk in patients with chest pain. <i>Clinical Biochemistry</i> , 2009, 42, 1012-1018.	1.9	26
56	Perioperative heart-type fatty acid binding protein is associated with acute kidney injury after cardiac surgery. <i>Kidney International</i> , 2015, 88, 576-583.	5.2	25
57	Effect of Repeat Measurements of High-Sensitivity Cardiac Troponin on the Same Sample Using the European Society of Cardiology 0-Hour/1-Hour or 2-Hour Algorithms for Early Rule-Out and Rule-In for Myocardial Infarction. <i>Clinical Chemistry</i> , 2017, 63, 1163-1165.	3.2	25
58	Analytical comparison of three different versions of a high-sensitivity cardiac troponin I assay over 10 years. <i>Clinica Chimica Acta</i> , 2017, 475, 51-55.	1.1	25
59	Health Outcomes Categorized by Current and Previous Definitions of Acute Myocardial Infarction in an Unselected Cohort of Troponin-Negative Emergency Department Patients. <i>Clinical Chemistry</i> , 2006, 52, 2028-2035.	3.2	24
60	Matrix and bilirubin interference for high-sensitivity cardiac troponin I. <i>Clinica Chimica Acta</i> , 2015, 442, 49-51.	1.1	24
61	Assessing Pneumatic Tube Systems with Patient-Specific Populations and Laboratory-Derived Criteria. <i>Clinical Chemistry</i> , 2012, 58, 792-795.	3.2	23
62	Cardiac Troponin Testing in Patients with COVID-19: A Strategy for Testing and Reporting Results. <i>Clinical Chemistry</i> , 2021, 67, 107-113.	3.2	23
63	Biomarkers for Predicting Serious Cardiac Outcomes at 72 Hours in Patients Presenting Early after Chest Pain Onset with Symptoms of Acute Coronary Syndromes. <i>Clinical Chemistry</i> , 2012, 58, 298-302.	3.2	22
64	Ninety-Minute vs 3-h Performance of High-Sensitivity Cardiac Troponin Assays for Predicting Hospitalization for Acute Coronary Syndrome. <i>Clinical Chemistry</i> , 2013, 59, 1407-1410.	3.2	22
65	High-Sensitivity Cardiac Troponin I for Predicting Death in a Female Emergency Department Population. <i>Clinical Chemistry</i> , 2014, 60, 271-273.	3.2	22
66	Emerging key laboratory tests for patients with COVID-19. <i>Clinical Biochemistry</i> , 2020, 81, 13-14.	1.9	22
67	Analytical factors to consider when assessing a high-sensitivity cardiac troponin I assay compared to a contemporary assay in clinical studies. <i>Clinica Chimica Acta</i> , 2014, 429, 6-7.	1.1	21
68	Educational Recommendations on Selected Analytical and Clinical Aspects of Natriuretic Peptides with a Focus on Heart Failure: A Report from the IFCC Committee on Clinical Applications of Cardiac Bio-Markers. <i>Clinical Chemistry</i> , 2019, 65, 1221-1227.	3.2	21
69	Rapid atrophy of cardiac left ventricular mass in patients with non-small cell carcinoma of the lung. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2019, 10, 1070-1082.	7.3	21
70	Variability Between Reagent Lots for High-Sensitivity Cardiac Troponin I May Affect Performance of Early Rule Out Strategies. <i>Canadian Journal of Cardiology</i> , 2018, 34, 209.e5-209.e6.	1.7	21
71	Challenges of implementing Point-of-Care Testing (POCT) glucose meters in a pediatric acute care setting. <i>Clinical Biochemistry</i> , 2004, 37, 811-817.	1.9	20
72	Effect of freeze-thaw and refrigeration conditions on high-sensitivity troponin T concentrations. <i>Annals of Clinical Biochemistry</i> , 2012, 49, 101-102.	1.6	20

#	ARTICLE	IF	CITATIONS
73	High-Sensitivity Cardiac Troponin Risk Cutoffs for Acute Cardiac Outcomes at Emergency Department Presentation. <i>Canadian Journal of Cardiology</i> , 2017, 33, 898-903.	1.7	20
74	Assessment of the 99th or 97.5th Percentile for Cardiac Troponin I in a Healthy Pediatric Cohort. <i>Clinical Chemistry</i> , 2014, 60, 1574-1576.	3.2	19
75	Profile of Roche's Elecsys Troponin T Gen 5 STAT blood test (a high-sensitivity cardiac troponin assay) for diagnosing myocardial infarction in the emergency department. <i>Expert Review of Molecular Diagnostics</i> , 2018, 18, 481-489.	3.1	19
76	Pediatric Feeding and Swallowing Problems: An Interdisciplinary Team Approach. <i>Canadian Journal of Dietetic Practice and Research</i> , 2006, 67, 185-190.	0.6	18
77	Centrifugation "an important pre-analytical factor for the Abbott Architect high-sensitivity cardiac troponin I assay. <i>Clinica Chimica Acta</i> , 2014, 436, 273-275.	1.1	18
78	Performance of high-sensitivity cardiac troponin in the emergency department for myocardial infarction and a composite cardiac outcome across different estimated glomerular filtration rates. <i>Clinica Chimica Acta</i> , 2018, 479, 166-170.	1.1	17
79	Sample matrix and high-sensitivity cardiac troponin I assays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, 745-751.	2.3	17
80	Sex-specific, high-sensitivity cardiac troponin T cut-off concentrations for ruling out acute myocardial infarction with a single measurement. <i>Canadian Journal of Emergency Medicine</i> , 2019, 21, 26-33.	1.1	17
81	Canadian society of clinical chemists (CSCC) interim consensus guidance for testing and reporting of SARS-CoV-2 serology. <i>Clinical Biochemistry</i> , 2020, 86, 1-7.	1.9	17
82	Macrocomplexes and high-sensitivity cardiac troponin assays in samples stored for over 15 years. <i>Clinica Chimica Acta</i> , 2020, 505, 6-8.	1.1	17
83	Cytokine elevations in acute coronary syndrome and ovarian cancer: A mechanism for the up-regulation of the acute phase proteins in these different disease etiologies. <i>Clinical Biochemistry</i> , 2008, 41, 607-610.	1.9	16
84	Dichotomizing High-Sensitivity Cardiac Troponin T Results and Important Analytical Considerations. <i>Journal of the American College of Cardiology</i> , 2012, 59, 1570.	2.8	15
85	Using the clinical chemistry score in the emergency department to detect adverse cardiac events: a diagnostic accuracy study. <i>CMAJ Open</i> , 2020, 8, E676-E684.	2.4	15
86	High sensitivity cardiac troponin concentration cutoffs "is a healthy population the right reference population for those with underlying cardiac disease?. <i>Clinical Biochemistry</i> , 2010, 43, 1037-1038.	1.9	14
87	Sex-specific cutoffs for cardiac troponin using high-sensitivity assays " Is there clinical equipoise?. <i>Clinical Biochemistry</i> , 2015, 48, 749-750.	1.9	14
88	Measurement of High-Sensitivity Cardiac Troponin in Pulmonary Embolism: Useful Test or a Clinical Distraction. <i>Seminars in Thrombosis and Hemostasis</i> , 2019, 45, 784-792.	2.7	14
89	Clinical evaluation of Ortho Clinical Diagnostics high-sensitivity cardiac Troponin I assay in patients with symptoms suggestive of acute coronary syndrome. <i>Clinical Biochemistry</i> , 2020, 80, 48-51.	1.9	14
90	Acute Phase Response and Non-Reproducible Elevated Concentrations with a High-Sensitivity Cardiac Troponin I Assay. <i>Journal of Clinical Medicine</i> , 2021, 10, 1014.	2.4	14

#	ARTICLE	IF	CITATIONS
91	Analytical assessment of ortho clinical diagnostics high-sensitivity cardiac troponin I assay. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 749-755.	2.3	14
92	“Upstream markers” provide for early identification of patients at high risk for myocardial necrosis and adverse outcomes. <i>Clinica Chimica Acta</i> , 2008, 387, 133-138.	1.1	13
93	Is a Pattern of Increasing Biomarker Concentrations Important for Long-Term Risk Stratification in Acute Coronary Syndrome Patients Presenting Early after the Onset of Symptoms?. <i>Clinical Chemistry</i> , 2008, 54, 747-751.	3.2	13
94	Assessment of a four hour delay for urine samples stored without preservatives at room temperature for urinalysis. <i>Clinical Biochemistry</i> , 2012, 45, 856-858.	1.9	13
95	Comparison of hs-cTnI, hs-cTnT, hFABP and GPBB for identifying early adverse cardiac events in patients presenting within six hours of chest pain-onset. <i>Clinica Chimica Acta</i> , 2013, 419, 39-41.	1.1	13
96	The potential role of a turbidimetric heart-type fatty acid-binding protein assay to aid in the interpretation of persistently elevated, non-changing, cardiac troponin I concentrations. <i>Clinical Biochemistry</i> , 2018, 58, 53-59.	1.9	13
97	An approach to rule-out an acute cardiovascular event or death in emergency department patients using outcome-based cutoffs for high-sensitivity cardiac troponin assays and glucose. <i>Clinical Biochemistry</i> , 2015, 48, 282-287.	1.9	12
98	Comprehensive Age and Sex 99th Percentiles for a High-Sensitivity Cardiac Troponin I Assay. <i>Clinical Chemistry</i> , 2018, 64, 398-399.	3.2	12
99	Analytical validation of cardiac troponin I assays in horses. <i>Journal of Veterinary Diagnostic Investigation</i> , 2018, 30, 226-232.	1.1	12
100	External Quality Assessment Testing Near the Limit of Detection for High-Sensitivity Cardiac Troponin Assays. <i>Clinical Chemistry</i> , 2018, 64, 1402-1404.	3.2	12
101	Analytical characterization of the Siemens Dimension EXL high-sensitivity cardiac troponin I assay. <i>Clinical Biochemistry</i> , 2019, 69, 52-56.	1.9	12
102	Comparison of two biomarker only algorithms for early risk stratification in patients with suspected acute coronary syndrome. <i>International Journal of Cardiology</i> , 2020, 319, 140-143.	1.7	12
103	The International Committee of Medical Journal Editors proposal for sharing clinical trial data and the possible implications for the peer review process. <i>Annals of Translational Medicine</i> , 2016, 4, 115-115.	1.7	12
104	Identification of myocardial injury in the emergency setting. <i>Clinical Biochemistry</i> , 2010, 43, 539-544.	1.9	11
105	Within-run precision and outlier detection for the Abbott ARCHITECT cardiac troponin I assay. <i>Annals of Clinical Biochemistry</i> , 2014, 51, 512-514.	1.6	11
106	Statistical issues with the determination of the troponin 99th percentile “ Not just a problem for troponin?. <i>Clinical Biochemistry</i> , 2016, 49, 1105-1106.	1.9	11
107	Economic Considerations of Early Rule-In/Rule-Out Algorithms for The Diagnosis of Myocardial Infarction in The Emergency Department Using Cardiac Troponin and Glycemic Biomarkers. <i>Clinical Chemistry</i> , 2017, 63, 593-602.	3.2	11
108	Definitions of post-coronary artery bypass grafting myocardial infarction: variations in incidence and prognostic significance. <i>European Journal of Cardio-thoracic Surgery</i> , 2020, 57, 168-175.	1.4	11

#	ARTICLE	IF	CITATIONS
109	High-Sensitivity Cardiac Troponinâ€”Optimizing the Diagnosis of Acute Myocardial Infarction/Injury in Women (CODE-MI): Rationale and design for a multicenter, stepped-wedge, cluster-randomized trial. <i>American Heart Journal</i> , 2020, 229, 18-28.	2.7	11
110	An Approach to Investigating Discordant High-Sensitivity Cardiac Troponin I Results. <i>Canadian Journal of Cardiology</i> , 2020, 37, 1292-1293.	1.7	11
111	Caution When Using High-Sensitivity Cardiac Troponin I Assay to Rule Out Acute Ischemia: When the Delta to Rule In Is Within Analytical Variation. <i>Canadian Journal of Cardiology</i> , 2020, 36, 1161.e11-1161.e12.	1.7	11
112	Sex-Specific Kinetics of High-Sensitivity Cardiac Troponin I and T following Symptom Onset and Early Presentation in Non-ST-Segment Elevation Myocardial Infarction. <i>Clinical Chemistry</i> , 2021, 67, 321-324.	3.2	11
113	Independent and combined effects of biotin and hemolysis on high-sensitivity cardiac troponin assays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, 1431-1443.	2.3	11
114	Storage conditions, sample integrity, interferences, and a decision tool for investigating unusual high-sensitivity cardiac troponin results. <i>Clinical Biochemistry</i> , 2023, 115, 67-76.	1.9	11
115	Quality control material testing and the importance of â€œtreating it like a patient's sampleâ€. <i>Clinical Biochemistry</i> , 2014, 47, 147-149.	1.9	10
116	Multicenter comparison of imprecision at low concentrations of two regulatory approved high-sensitivity cardiac troponin I assays. <i>Clinica Chimica Acta</i> , 2018, 486, 219-220.	1.1	10
117	Clinical outcomes for chest pain patients discharged home from emergency departments using high-sensitivity versus conventional cardiac troponin assays. <i>American Heart Journal</i> , 2020, 221, 84-94.	2.7	10
118	Association of plasma-soluble ST2 and galectin-3 with cardiovascular events and mortality following cardiac surgery. <i>American Heart Journal</i> , 2020, 220, 253-263.	2.7	10
119	Disagreement between Cardiac Troponin Tests Yielding a Higher Incidence of Myocardial Injury in the Emergency Setting. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 31.	1.6	10
120	The use of a cytokine panel to define the long-term risk stratification of heart failure/death in patients presenting with chest pain to the emergency department. <i>Clinical Biochemistry</i> , 2010, 43, 505-507.	1.9	9
121	Sensitive and high sensitivity cardiac troponin I concentrations in the Heart Outcomes Prevention Evaluation (HOPE) study â€” A high risk population. <i>Clinica Chimica Acta</i> , 2010, 411, 1832.	1.1	9
122	Early standardization of high sensitivity troponin T reporting - a lost opportunity. <i>Clinical Biochemistry</i> , 2011, 44, 758-759.	1.9	9
123	Assessing the necessity of including a crossover period with dual reporting when changing total prostate-specific antigen methods. <i>Clinical Biochemistry</i> , 2014, 47, 897-900.	1.9	9
124	Hospital Admission and Myocardial Injury Prevalence after the Clinical Introduction of a High-Sensitivity Cardiac Troponin I Assay. <i>Clinical Chemistry</i> , 2015, 61, 1209-1210.	3.2	9
125	Best Practices for Monitoring Cardiac Troponin in Detecting Myocardial Injury. <i>Clinical Chemistry</i> , 2017, 63, 37-44.	3.2	9
126	A Three-Site Immunoassay for High-Sensitivity Cardiac Troponin I with Low Immunoreactivity for Macrocomplexes. <i>Clinical Chemistry</i> , 2020, 66, 854-855.	3.2	9

#	ARTICLE	IF	CITATIONS
127	Analytical performance of cardiac troponin assays – Current status and future needs. <i>Clinica Chimica Acta</i> , 2020, 509, 149-155.	1.1	9
128	Misclassification of Myocardial Injury by a High-Sensitivity Cardiac Troponin I Assay. <i>Canadian Journal of Cardiology</i> , 2021, 37, 523.e7-523.e8.	1.7	9
129	Diagnostic Performance of Serial High-Sensitivity Cardiac Troponin Measurements in the Emergency Setting. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 97.	1.6	9
130	High-Five for High-Sensitivity Cardiac Troponin T: Depends on the Precision and Analytical Platform. <i>JAMA Internal Medicine</i> , 2013, 173, 477.	5.1	8
131	Cardiac and Inflammation Biomarker Profile after Initiation of Adjuvant Trastuzumab Therapy. <i>Clinical Chemistry</i> , 2013, 59, 327-329.	3.2	8
132	Adopting ng/L™ as the units for high-sensitivity cardiac troponin assays and commitment by the entire health-care team could be the key for adopting recommendations. <i>Annals of Clinical Biochemistry</i> , 2016, 53, 516-517.	1.6	8
133	A laboratory score at presentation to rule-out serious cardiac outcomes or death in patients presenting with symptoms suggestive of acute coronary syndrome. <i>Clinica Chimica Acta</i> , 2017, 469, 69-74.	1.1	8
134	Should detectable cardiac troponin concentrations in a healthy population be the only criterion for classifying high-sensitivity cardiac troponin assays?. <i>Clinical Biochemistry</i> , 2018, 56, 1-3.	1.9	8
135	Development of biomarker combinations for postoperative acute kidney injury via Bayesian model selection in a multicenter cohort study. <i>Biomarker Research</i> , 2018, 6, 3.	6.8	8
136	A Multicenter Assessment of the Sensitivity and Specificity for a Single High-Sensitivity Cardiac Troponin Test at Emergency Department Presentation for Hospital Admission. <i>Journal of Applied Laboratory Medicine</i> , 2019, 4, 170-179.	1.3	8
137	Preoperative prediction of Bleeding Independently associated with Mortality after noncardiac Surgery (BIMS): an international prospective cohort study. <i>British Journal of Anaesthesia</i> , 2021, 126, 172-180.	3.4	8
138	Biochip arrays for the discovery of a biomarker surrogate in a phase I/II study assessing a novel anti-metastasis agent. <i>Clinical Biochemistry</i> , 2009, 42, 1162-1165.	1.9	7
139	Canadian Institutes of Health Research dissemination grant on high-sensitivity cardiac troponin. <i>Clinical Biochemistry</i> , 2014, 47, 155-157.	1.9	7
140	Effect of a low glycemic index diet versus a high-cereal fibre diet on markers of subclinical cardiac injury in healthy individuals with type 2 diabetes mellitus: An exploratory analysis of a randomized dietary trial. <i>Clinical Biochemistry</i> , 2017, 50, 1104-1109.	1.9	7
141	Chloride and Other Electrolyte Concentrations in Commonly Available 5% Albumin Products. <i>Critical Care Medicine</i> , 2018, 46, e326-e329.	0.9	7
142	Four Different High-Sensitivity Cardiac Troponin Assays With Important Analytical Performance Differences. <i>Canadian Journal of Cardiology</i> , 2019, 35, 796.e17-796.e18.	1.7	7
143	Between-day versus within-day imprecision using the Abbott high-sensitivity cardiac troponin I assay at concentrations around 5 ng/l. <i>Clinica Chimica Acta</i> , 2019, 489, 58-60.	1.1	7
144	Pre-analytical variables affecting discordant results on repeat sample testing for cardiac troponin I. <i>Clinical Biochemistry</i> , 2019, 63, 158-160.	1.9	7

#	ARTICLE	IF	CITATIONS
145	Lot-to-Lot Variation for Commercial High-Sensitivity Cardiac Troponin: Can We Realistically Report Down to the Assay's Limit of Detection?. <i>Clinical Chemistry</i> , 2020, 66, 1146-1149.	3.2	7
146	High-Sensitivity Cardiac Troponin I vs a Clinical Chemistry Score for Predicting All-Cause Mortality in an Emergency Department Population. <i>CJC Open</i> , 2020, 2, 296-302.	1.5	7
147	Additional approaches for identifying non-reproducible cardiac troponin results. <i>Clinical Chemistry and Laboratory Medicine</i> , 2021, 59, e267-e270.	2.3	7
148	Clinical chemistry tests for patients with COVID-19 – important caveats for interpretation. <i>Clinical Chemistry and Laboratory Medicine</i> , 2020, 58, 1142-1143.	2.3	7
149	Vascular versus myocardial dysfunction in acute coronary syndrome: Are the adhesion molecules as powerful as NT-proBNP for long-term risk stratification?. <i>Clinical Biochemistry</i> , 2008, 41, 436-439.	1.9	6
150	Letter by Kavsak and MacRae Regarding Article, "Utility of Absolute and Relative Changes in Cardiac Troponin Concentrations in the Early Diagnosis of Acute Myocardial Infarction". <i>Circulation</i> , 2012, 125, e358; author reply e359.	1.6	6
151	For a rapid diagnosis of acute myocardial infarction, a sensitive troponin assay is needed in the near-patient testing setting. <i>Expert Review of Cardiovascular Therapy</i> , 2012, 10, 309-312.	1.5	6
152	A step closer in reducing hemolysis in blood samples collected in the emergency department. <i>Clinical Biochemistry</i> , 2013, 46, 565.	1.9	6
153	Metrics for identifying errors related to pre-analytical sample handling. <i>Clinical Biochemistry</i> , 2014, 47, 989-990.	1.9	6
154	A heterophile antibody affecting a contemporary but not a high-sensitivity cardiac troponin assay. <i>Clinical Biochemistry</i> , 2019, 71, 72-73.	1.9	6
155	Risk Stratification for Patients with Chest Pain Discharged Home from the Emergency Department. <i>Journal of Clinical Medicine</i> , 2020, 9, 2948.	2.4	6
156	A Randomized Phase II Trial of Prostate Boost Irradiation With Stereotactic Body Radiotherapy (SBRT) or Conventional Fractionation (CF) External Beam Radiotherapy (EBRT) in Locally Advanced Prostate Cancer: The APBS Trial (NCT03380806). <i>Clinical Genitourinary Cancer</i> , 2020, 18, e410-e415.	1.9	6
157	Side-Effects of COVID-19 on Patient Care: An INR Story. <i>Journal of Applied Laboratory Medicine</i> , 2021, 6, 953-961.	1.3	6
158	Authors' response to Apple editorial. <i>Clinica Chimica Acta</i> , 2007, 380, 245-246.	1.1	5
159	Highly Sensitive Cardiac Troponin T Assay, Cardiac Disease, and Mortality Risk. <i>JAMA - Journal of the American Medical Association</i> , 2011, 305, 1196.	7.4	5
160	The ABCs of clinical biochemistry. <i>Clinical Biochemistry</i> , 2012, 45, 1-2.	1.9	5
161	Clinical Biochemistry year in review – The clinical "good", the analytical "bad", and the "ugly" laboratory practices. <i>Clinical Biochemistry</i> , 2014, 47, 255-256.	1.9	5
162	Reality check for cardiac troponin testing – "Sometimes the result is wrong. <i>Clinical Biochemistry</i> , 2016, 49, 1107-1108.	1.9	5

#	ARTICLE	IF	CITATIONS
163	Analytical Variation and Abbott Diagnostics High-Sensitivity Cardiac Troponin I Risk Categories in Asymptomatic Individuals. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1605.e7-1605.e8.	1.7	5
164	Commercial Quality Control Imprecision Estimates for High-Sensitivity Cardiac Troponin Deltas Used to Rule-in Myocardial Infarction with the ESC 0/1-Hour Algorithm. <i>Journal of Applied Laboratory Medicine</i> , 2020, 5, 1122-1124.	1.3	5
165	The effect of the Covid-19 shutdown on glycemic testing and control. <i>Clinica Chimica Acta</i> , 2021, 519, 148-152.	1.1	5
166	Impact of Switching Sample Types for High-Sensitivity Cardiac Troponin I Assays in the 0/1 Hour Algorithms. <i>Clinical Chemistry</i> , 2021, 67, 319-321.	3.2	5
167	Determination of 97.5th and 99th percentile upper reference limits for heart-type fatty acid-binding protein (H-FABP) in a US population. <i>Clinica Chimica Acta</i> , 2021, 523, 397-401.	1.1	5
168	Measurement in different sample types may aid in detecting interferences and macrocomplexes affecting cardiac troponin measurements. <i>Clinical Chemistry and Laboratory Medicine</i> , 2022, 60, 66-67.	2.3	5
169	Another potential marker linking gender and cardiac mortality: PAPP-A – A new marker in risk stratification for women presenting with chest pain. <i>Clinica Chimica Acta</i> , 2009, 408, 139-140.	1.1	4
170	High-Sensitivity Cardiac Troponin Assays – Change Is Important. <i>Clinical Chemistry</i> , 2012, 58, 311-313.	3.2	4
171	Statistical and analytical approaches for assessing biomarkers: New approaches, new technologies, with the same-old rigor for evaluation. <i>Clinical Biochemistry</i> , 2012, 45, 187-188.	1.9	4
172	Considerations for establishing a reference interval for elderly individuals in the emergency department with the high-sensitivity cardiac troponin T assay. <i>Clinica Chimica Acta</i> , 2013, 421, 85-86.	1.1	4
173	Persistent Increases in Cardiac Troponin Concentrations As Measured with High-Sensitivity Assays after Acute Myocardial Infarction. <i>Clinical Chemistry</i> , 2013, 59, 443-445.	3.2	4
174	What is in that sample? A pertinent question when assessing quality for patient laboratory results and beyond. <i>Clinical Biochemistry</i> , 2015, 48, 465-466.	1.9	4
175	Targeted metabolomics in colorectal cancer: a strategic approach using standardized laboratory tests of the blood and urine. <i>Hypoxia (Auckland, N Z)</i> , 2017, Volume 5, 61-66.	1.9	4
176	Longitudinal High-Sensitivity Cardiac Troponin I Measurements in Patients With Breast Cancer Receiving Trastuzumab. <i>Canadian Journal of Cardiology</i> , 2019, 35, 545.e1-545.e2.	1.7	4
177	ASSOCIATION BETWEEN HIGH-SENSITIVITY TROPONIN I AND MAJOR CARDIOVASCULAR EVENTS AFTER NON-CARDIAC SURGERY. <i>Journal of the American College of Cardiology</i> , 2020, 75, 110.	2.8	4
178	Important Differences Between Manufacturers When Transitioning From a Contemporary Cardiac Troponin Assay to a High-Sensitivity Cardiac Troponin Assay. <i>CJC Open</i> , 2021, 3, 841-842.	1.5	4
179	Sex-Specific Absolute Delta Thresholds for High-Sensitivity Cardiac Troponin T. <i>Clinical Chemistry</i> , 2022, 68, 441-449.	3.2	4
180	A STAR-Document for those interested in evaluating diagnostic research studies. <i>Annals of Translational Medicine</i> , 2016, 4, 45.	1.7	4

#	ARTICLE	IF	CITATIONS
181	Vascular Endothelial Growth Factor Concentration as a Predictive Marker: Ready for Primetime?. <i>Clinical Cancer Research</i> , 2010, 16, 1341-1341.	7.0	3
182	Cardiac Troponin Cutoffs: The Importance of Assay Sensitivity and the Patient Population. <i>Journal of Clinical Oncology</i> , 2011, 29, e177-e177.	1.6	3
183	An Alternative Approach for Detecting Interferences in Enzymatic Acetaminophen Assays. <i>Clinical Chemistry</i> , 2011, 57, 1203-1204.	3.2	3
184	Root cause analysis of delays to discharge for patients held for serial cardiac troponin levels. <i>Canadian Journal of Emergency Medicine</i> , 2014, 16, 20-24.	1.1	3
185	Cytokines and cell adhesion molecules exhibit distinct profiles in health, ovarian cancer, and breast cancer. <i>Heliyon</i> , 2016, 2, e00059.	3.2	3
186	High-sensitivity cardiac troponin concentrations at emergency department presentation in females and males with an acute cardiac outcome. <i>Annals of Clinical Biochemistry</i> , 2018, 55, 604-607.	1.6	3
187	The importance of tumour marker dual reporting during method transition: PSA high-dose hook effect detected. <i>Clinical Biochemistry</i> , 2018, 61, 45-46.	1.9	3
188	Long-term quality control testing on a high-sensitivity cardiac troponin I assay. <i>Clinica Chimica Acta</i> , 2019, 498, 27-29.	1.1	3
189	Effect of Storage Temperature for B-Type Natriuretic Peptide Concentrations for Primary Healthcare Populations. <i>Clinical Chemistry</i> , 2019, 65, 811-812.	3.2	3
190	Detection of repeated positive result biases for a high-sensitivity cardiac troponin I assay. <i>Clinica Chimica Acta</i> , 2020, 510, 242-243.	1.1	3
191	A Large Number of Fresh Samples and a Wide Range of Total Prostate-Specific Antigen (tPSA) Concentrations Is Important to Detect Differences in PSA Methods. <i>Clinical Chemistry</i> , 2021, 67, 1155-1157.	3.2	3
192	Repeat measurements on patient samples identifies unpredictable and poorly reproducible cardiac troponin results with a high-sensitivity cardiac troponin assay. <i>Annals of Clinical Biochemistry</i> , 2021, 58, 677-679.	1.6	3
193	Clinical chemistry score misses fewer deaths as compared to troponin T alone in a United States emergency department population. <i>Clinical Biochemistry</i> , 2021, 95, 91-92.	1.9	3
194	Variability in Cardiac Biomarkers during Hemodialysis: A Prospective Cohort Study. <i>Clinical Chemistry</i> , 2021, 67, 308-316.	3.2	3
195	Imprecision and Delta Criteria for a New ESC 0/2-Hour Algorithm. <i>Clinical Chemistry</i> , 2022, 68, 721-722.	3.2	3
196	Peripheral Blood Monocyte Subset Assessment in Non- σ ST-Segment Elevation Myocardial Infarction Is Required. <i>Journal of the American College of Cardiology</i> , 2010, 55, 169.	2.8	2
197	Multiplex protein assay performance/evaluation and the requirement for precision and correlation to clinical assays. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1915-8.	2.3	2
198	Troponin levels in hemodialysis patients: interpretation based on guidelines, changing concentrations and high-sensitivity assays. <i>Nephrology Dialysis Transplantation</i> , 2011, 26, 1112-1113.	0.7	2

#	ARTICLE	IF	CITATIONS
199	Whether it is personalized, precision, or mechanistic medicine - the clinical laboratory has a role. <i>Clinical Biochemistry</i> , 2012, 45, 384.	1.9	2
200	Presenting characteristics of patients undergoing cardiac troponin measurements in the emergency department. <i>Canadian Journal of Emergency Medicine</i> , 2015, 17, 62-66.	1.1	2
201	Carryover: More than just a major hangover for the clinical laboratory. <i>Clinical Biochemistry</i> , 2016, 49, 735-736.	1.9	2
202	Error detection in routine clinical chemistry laboratory test results. <i>Clinical Biochemistry</i> , 2016, 49, 199-200.	1.9	2
203	Perioperative heart-type fatty acid binding protein concentration cutoffs for the identification of severe acute kidney injury in patients undergoing cardiac surgery. <i>Clinical Chemistry and Laboratory Medicine</i> , 2018, 57, e8-e10.	2.3	2
204	High-sensitivity troponin testing months after an acute coronary syndrome: noise or notable results. <i>Heart</i> , 2019, 105, 1688-1690.	2.9	2
205	Admission High-Sensitivity Cardiac Troponin vs a Biochemical Score for Predicting Mortality in Patients With COVID-19. <i>CJC Open</i> , 2021, 3, 130-131.	1.5	2
206	Letter by Hwang et al Regarding Article, "Temporal Release of High-Sensitivity Cardiac Troponin T and I and Copeptin After Brief Induced Coronary Artery Balloon Occlusion in Humans" <i>Circulation</i> , 2021, 144, e166-e167.	1.6	2
207	Can the Addition of NT-proBNP and Glucose Measurements Improve the Prognostication of High-Sensitivity Cardiac Troponin Measurements for Patients with Suspected Acute Coronary Syndrome?. <i>Journal of Cardiovascular Development and Disease</i> , 2021, 8, 106.	1.6	2
208	Cardiotoxicity associated with sunitinib. <i>Lancet, The</i> , 2008, 371, 1244.	18.7	1
209	Serial cardiac troponin T measurements in haemodialysis patients: absolute versus changing concentrations?. <i>Annals of Clinical Biochemistry</i> , 2010, 47, 97-97.	1.6	1
210	Clinical Biochemistry 2015 year in review: Material not for the faint of heart. <i>Clinical Biochemistry</i> , 2015, 48, 1211-1212.	1.9	1
211	1448: CHLORIDE CONCENTRATION OF COMMONLY AVAILABLE 5% HUMAN ALBUMIN SOLUTIONS. <i>Critical Care Medicine</i> , 2016, 44, 437-437.	0.9	1
212	Can 100 papers over 50 years tell the story of a scientific journal?. <i>Clinical Biochemistry</i> , 2017, 50, 1-5.	1.9	1
213	High-STEACS Algorithm missed fewer patients with acute MI than the ESC Pathway in the ED. <i>Annals of Internal Medicine</i> , 2017, 167, JC34.	3.9	1
214	Editorial commentary: High-sensitivity cardiac troponin: Like every new tool there is a learning curve. <i>Trends in Cardiovascular Medicine</i> , 2017, 27, 48-50.	4.9	1
215	Differences in total PSA results within and between manufacturers. <i>Clinical Biochemistry</i> , 2018, 60, 91-92.	1.9	1
216	High-sensitivity cardiac troponin testing during and after ACS: Complexed or not?. <i>Clinical Biochemistry</i> , 2019, 73, 32-34.	1.9	1

#	ARTICLE	IF	CITATIONS
217	A post-hoc subgroup analysis assessing acute cardiac biomarker profiles in female cancer patients during adjuvant therapy. <i>Clinica Chimica Acta</i> , 2019, 495, 355-357.	1.1	1
218	Biomarkers for coronary artery disease and heart failure. , 2020, , 519-543.		1
219	High-Sensitivity Cardiac Troponin T Testing and Cardiovascular Outcomes at 30 Days and 1 Year in Patients Discharged Home from the Emergency Department with Chest Pain. <i>journal of applied laboratory medicine, The</i> , 2020, 5, 821-824.	1.3	1
220	Approaching 2020 acuity for high-sensitivity cardiac troponin assays in <i>Clinical Biochemistry</i> . <i>Clinical Biochemistry</i> , 2020, 78, 1-3.	1.9	1
221	Biomarker Testing Considerations in the Evaluation and Management of Patients With Heart Failure: Perspectives From the International Federation of Clinical Chemistry and Laboratory Medicine Committee. <i>Journal of Cardiac Failure</i> , 2021, 27, 1456-1461.	1.7	1
222	Combination of lymphocyte count and not the serological response with high-sensitivity cardiac troponin for risk stratification in patients with possible COVID-19. <i>Clinica Chimica Acta</i> , 2021, 519, 306-307.	1.1	1
223	Single troponin to rule-out MI in early presenters, perhaps, but not major adverse cardiac events. <i>International Journal of Cardiology</i> , 2021, 342, 29-30.	1.7	1
224	The imprecision for a high-sensitivity cardiac troponin assay and a CA 19-9 assay in samples with high C-reactive protein concentrations. <i>Clinica Chimica Acta</i> , 2021, 524, 192-192.	1.1	1
225	Low-risk cutoff of 90Âml/min/1.73Âm ² for the estimated glomerular filtration rate and the importance of the equation for patients with acute coronary syndrome. <i>Clinica Chimica Acta</i> , 2021, 523, 532-533.	1.1	1
226	High-sensitivity cardiac troponin and the importance of cutoffs in patients with prior coronary artery bypass grafting with suspected NSTEMI. <i>International Journal of Cardiology</i> , 2022, 356, 36-37.	1.7	1
227	Autism spectrum disorder: When biochemical and genetic profiles don't match " Is sample size and selection bias the culprit?. <i>Clinical Biochemistry</i> , 2011, 44, 1358.	1.9	0
228	Letter by Kavsak et al Regarding Article, "B-Type Natriuretic Peptide Signal Peptide Circulates in Human Blood: Evaluation as a Potential Biomarker of Cardiac Ischemia" • <i>Circulation</i> , 2011, 123, e233; author reply e234.	1.6	0
229	Risk Stratification in the Era of High-Sensitivity Troponin Assays. <i>Annals of Emergency Medicine</i> , 2012, 59, 126-127.	0.6	0
230	International comparisons of acute myocardial infarction. <i>Lancet, The</i> , 2014, 384, 304.	13.7	0
231	Negative interference of N-acetyl cysteine (NAC) on selected chemistries on the Abbott architect platform. <i>Clinica Chimica Acta</i> , 2015, 451, 219-221.	1.1	0
232	Response by Than et al to Letter Regarding Article, "Assessment of the European Society of Cardiology 0-Hour/1-Hour Algorithm to Rule-Out and Rule-In Acute Myocardial Infarction" • <i>Circulation</i> , 2017, 135, e923-e924.	1.6	0
233	4 hs-cTnl algorithms had high sensitivity and low failure rates for ruling out acute MI in the ED. <i>Annals of Internal Medicine</i> , 2017, 167, JC35.	3.9	0
234	The importance of the methodology and sample matrix when interpreting chromogranin A results. <i>Clinical Chemistry and Laboratory Medicine</i> , 2019, 57, e291-e293.	2.3	0

#	ARTICLE	IF	CITATIONS
235	The PROTROPIC feasibility study: prognostic value of elevated troponins in critical illness. Canadian Journal of Anaesthesia, 2019, 66, 648-657.	1.6	0
236	The Evidence for Laboratory Testâ€‘Based Computer Clinical Decision Support Tools on Medication Errors and Adverse Drug Events. journal of applied laboratory medicine, The, 2019, 3, 922-924.	1.3	0
237	206: A Randomized Phase II Trial of Prostate Boost Irradiation with Stereotactic Body Radiotherapy (SBRT) in High-Risk Prostate Cancer. The Pbs Trial. Radiotherapy and Oncology, 2020, 150, S87-S88.	0.6	0
238	Stressing the Utility of High-Sensitivity Cardiac Troponin Testing in Patients with Possible Cardiac Ischemia. journal of applied laboratory medicine, The, 2017, 1, 468-470.	1.3	0
239	Combination of antibody tests against SARS-CoV-2 for health care workers after vaccination. Clinical Biochemistry, 2021, , .	1.9	0